Patents by Inventor Maria Arico
Maria Arico has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 10864262Abstract: Gram-negative bacterial strains are generated by inactivating at least one LytM catalytic domain-containing protein, such as NT013, NT017 and NT022 of non typeable H influenzae. The vesicles from these strains are useful for vaccination.Type: GrantFiled: April 24, 2014Date of Patent: December 15, 2020Assignee: GLAXOSMITHKLINE BIOLOGICALS SAInventors: Maria Arico, Giuseppe Ercoli, Nathalie Norais, Marco Soriani, Chiara Tani
-
Patent number: 10596246Abstract: The M01573 sequence of meningococcal fHbp offers poor coverage in a vaccine. The invention addresses this poor coverage in two ways. In a first aspect, a fHbp-based vaccine includes two family I fHbp sequences, one which is more closely related to MC58 than to M01573, and vice versa. In a second aspect, a multi-family fHbp-based vaccine uses a family I fHbp sequence which is more closely related to MC58 than to M01573, in combination with a family III fHbp sequence. The compositions are adjuvanted with an aluminium phosphate adjuvant.Type: GrantFiled: December 29, 2011Date of Patent: March 24, 2020Assignee: GLAXOSMITHKLINE BIOLOGICAL SAInventors: Beatrice Maria Arico, Brunella Brunelli, Maurizio Comanducci, Mariagrazia Pizza, Silvana Savino, Maria Scarselli
-
Patent number: 10478483Abstract: The M01573 sequence of meningococcal fHbp offers poor coverage in a vaccine. The invention addresses this poor coverage in two ways. In a first aspect, a fHbp-based vaccine includes two family I fHbp sequences, one which is more closely related to MC58 than to M01573, and vice versa. In a second aspect, a multi-family fHbp-based vaccine uses a family I fHbp sequence which is more closely related to MC58 than to M01573, in combination with a family III fHbp sequence.Type: GrantFiled: June 24, 2011Date of Patent: November 19, 2019Assignee: GLAXOSMITHKLINE BIOLOGICALS SAInventors: Maria Aricò, Brunella Brunelli, Maurizio Comanducci, Mariagrazia Pizza, Silvana Savino, Maria Scarselli
-
Patent number: 9694063Abstract: The present invention relates to recombinant fragments of C. difficile TcdA and TcdB that may be used in the development of vaccines against C. difficile associated disease. More particularly it relates to combinations comprising a ToxB-GT antigen and a TcdA antigen or a ToxA-GT antigen and a TcdB antigen.Type: GrantFiled: December 7, 2012Date of Patent: July 4, 2017Assignee: GLAXOSMITHKLINE BIOLOGICALS SAInventors: Maria Scarselli, Mariagrazia Pizza, Rosanna Leuzzi, Maria Arico, Manuele Martinelli, Gillian Douce
-
Publication number: 20170080077Abstract: Alternative and improved approaches to the heterologous expression of the proteins of Neisseria meningitidis and Neisseria gonorrhoeae are disclosed. These approaches typically affect the level of expression, the ease of purification, the cellular localization, and/or the immunological properties of the expressed protein.Type: ApplicationFiled: December 2, 2016Publication date: March 23, 2017Applicant: GlaxoSmithKline Biologicals SAInventors: Maria ARICÒ, Maurizio COMANDUCCI, Cesira GALEOTTI, Vega MASIGNANI, Marzia Monica GIULIANI, Mariagrazia PIZZA
-
Publication number: 20170080076Abstract: Alternative and improved approaches to the heterologous expression of the proteins of Neisseria meningitidis and Neisseria gonorrhoeae are disclosed. These approaches typically affect the level of expression, the ease of purification, the cellular localization, and/or the immunological properties of the expressed protein.Type: ApplicationFiled: December 2, 2016Publication date: March 23, 2017Applicant: GlaxoSmithKline Biologicals SAInventors: Maria ARICÒ, Maurizio COMANDUCCI, Cesira GALEOTTI, Vega MASIGNANI, Marzia Monica GIULIANI, Mariagrazia PIZZA
-
Patent number: 9579372Abstract: fHBP is a protein in Neisseria meningitidis. Three families of fHBP are known. To increase the ability of a fHBP protein to elicit antibodies that are cross-reactive between the families, fHBP is selected or engineered to have a sequence which can elicit broad-spectrum bactericidal anti-meningococcal antibodies after administration to a host animal.Type: GrantFiled: February 20, 2009Date of Patent: February 28, 2017Assignee: GlaxoSmithKline Biologicals SAInventors: Mariagrazia Pizza, Maria Scarselli, Marzia Monica Giuliani, Maria Arico, Rino Rappuoli
-
Patent number: 9468673Abstract: fHBP is a protein in Neisseria meningitidis. Three families of fHBP are known. To increase the ability of a fHBP protein to elicit antibodies that are cross-reactive between the families, fHBP is selected or engineered to have a sequence which can elicit broad-spectrum bactericidal anti-meningococcal antibodies after administration to a host animal.Type: GrantFiled: January 8, 2013Date of Patent: October 18, 2016Assignee: GlaxoSmithKline Biologicals SAInventors: Mariagrazia Pizza, Maria Scarselli, Marzia Monica Giuliani, Maria Arico, Rino Rappuoli
-
Publication number: 20160067326Abstract: Gram-negative bacterial strains are generated by inactivating at least one LytM catalytic domain-containing protein, such as NT013, NT017 and NT022 of non typeable H influenzae. The vesicles from these strains are useful for vaccination.Type: ApplicationFiled: April 24, 2014Publication date: March 10, 2016Applicant: GlaxoSmithKline Biologicals s.a.Inventors: Maria ARICO, Giuseppe ERCOLI, Nathalie NORAIS, Marco SORIANI, Chiara TANI
-
Patent number: 9267163Abstract: Two or more Neisserial proteins (e.g. A and B) are expressed as a single hybrid protein which can be represented simply by the formula NH2-A-B—COOH.Type: GrantFiled: February 25, 2005Date of Patent: February 23, 2016Assignee: GlaxoSmithKline Biologicals SAInventors: Maria Aricò, Maurizio Comanducci, Cesira Galeotti, Vega Masignani, Marzia Monica Giuliani, Mariagrazia Pizza
-
Patent number: 9249197Abstract: NadA, App and ORF40 function as adhesins in N. meningitidis. Adhesion nad be modulated by targeting these three proteins. NadA allelic variants are also disclosed. Autoproteolytic cleavage of App is disclosed, as is removal of the activity by mutagenesis. App is processed and secreted into culture medium when expressed in E. coli. Mature App proteins are disclosed. Knockout mutants are disclosed. Vesicles from non-Neisserial hosts with heterologous adhesion expression are disclosed.Type: GrantFiled: March 24, 2014Date of Patent: February 2, 2016Assignee: GlaxoSmithKline Biologicals SAInventors: Maria Arico, Maurizio Comanducci
-
Patent number: 9150898Abstract: Alternative and improved approaches to the heterologous expression of the proteins of Neisseria meningitidis and Neisseria gonorrhoeae are disclosed. These approaches typically affect the level of expression, the ease of purification, the cellular localization, and/or the immunological properties of the expressed protein.Type: GrantFiled: July 31, 2014Date of Patent: October 6, 2015Assignee: GlaxoSmithKline Biologicals SAInventors: Maria Aricò, Maurizio Comanducci, Cesira Galeotti, Vega Masignani, Marzia Monica Giuliani, Mariagrazia Pizza
-
Patent number: 9102729Abstract: Polypeptides comprising non-typeable Haemophilus influenzae (NTHi) amino acid sequences. Over 2500 specific NTHi proteins are disclosed. The invention also provides related polypeptides, nucleic acids, antibodies and methods. These can all be used in medicine for treating or preventing disease and/or infection caused by H. influenzae, such as otitis media.Type: GrantFiled: April 29, 2014Date of Patent: August 11, 2015Assignee: Novartis Vaccines and Diagnostics SRLInventors: Vega Masignani, Beatrice Maria Arico
-
Publication number: 20150209419Abstract: The M01573 sequence of meningococcal fHbp offers poor coverage in a vaccine. The invention addresses this poor coverage in two ways. In a first aspect, a fHbp-based vaccine includes two family I fHbp sequences, one which is more closely related to MC58 than to M01573, and vice versa. In a second aspect, a multi-family fHbp-based vaccine uses a family I fHbp sequence which is more closely related to MC58 than to M01573, in combination with a family III fHbp sequence. The compositions are adjuvanted with an aluminium phosphate adjuvant.Type: ApplicationFiled: December 29, 2011Publication date: July 30, 2015Inventors: Beatrice Maria Arico, Brunella Brunelli, Maurizio Comanducci, Mariagrazia Pizza, Silvana Savino, Maria Scarselli
-
Publication number: 20150132333Abstract: The present invention relates to recombinant fragments of C. difficile TcdA and TcdB that may be used in the development of vaccines against C. difficile associated disease. More particularly it relates to combinations comprising a ToxB-GT antigen and a TcdA antigen or a ToxA-GT antigen and a TcdB antigen.Type: ApplicationFiled: December 7, 2012Publication date: May 14, 2015Inventors: Maria Scarselli, Mariagrazia Pizza, Rosanna Leuzzi, Maria Arico, Manuele Martinelli, Gillian Douce
-
Publication number: 20140363462Abstract: Alternative and improved approaches to the heterologous expression of the proteins of Neisseria meningitidis and Neisseria gonorrhoeae are disclosed. These approaches typically affect the level of expression, the ease of purification, the cellular localization, and/or the immunological properties of the expressed protein.Type: ApplicationFiled: July 31, 2014Publication date: December 11, 2014Inventors: Maria ARICÒ, Maurizio COMANDUCCI, Cesira GALEOTTI, Vega MASIGNANI, Marzia Monica GIULIANI, Mariagrazia PIZZA
-
Publication number: 20140294884Abstract: NadA, App and ORF40 function as adhesins in N. meningitidis. Adhesion nad be modulated by targeting these three proteins. NadA allelic variants are also disclosed. Autoproteolytic cleavage of App is disclosed, as is removal of the activity by mutagenesis. App is processed and secreted into culture medium when expressed in E. coli. Mature App proteins are disclosed. Knockout mutants are disclosed. Vesicles from non-Neisserial hosts with heterologous adhesion expression are disclosed.Type: ApplicationFiled: March 24, 2014Publication date: October 2, 2014Applicant: NOVARTIS VACCINES AND DIAGNOSTICS SRLInventors: Maria ARICO, Maurizio COMANDUCCI
-
Publication number: 20140234363Abstract: Polypeptides comprising non-typeable Haemophilus influenzae (NTHi) amino acid sequences. Over 2500 specific NTHi proteins are disclosed. The invention also provides related polypeptides, nucleic acids, antibodies and methods. These can all be usedin medicine for treating or preventing disease and/or infection caused by H. influenzae, such as otitis media.Type: ApplicationFiled: April 29, 2014Publication date: August 21, 2014Applicant: Novartis Vaccines and Diagnostics SRLInventors: Vega Masignani, Beatrice Maria Arico
-
Publication number: 20130189295Abstract: The M01573 sequence of meningococcal fHbp offers poor coverage in a vaccine. The invention addresses this poor coverage in two ways. In a first aspect, a fHbp-based vaccine includes two family I fHbp sequences, one which is more closely related to MC58 than to M01573, and vice versa. In a second aspect, a multi-family fHbp-based vaccine uses a family I fHbp sequence which is more closely related to MC58 than to M01573, in combination with a family III fHbp sequence.Type: ApplicationFiled: June 24, 2011Publication date: July 25, 2013Applicant: Novartis AGInventors: Maria Aricò, Brunella Brunelli, Maurizio Comanducci, Mariagrazia Pizza, Silvana Savino, Maria Scarselli
-
Patent number: 8334114Abstract: Meningococcal antigens are cleaved by human lactoferrin. The invention is based on the identification of the cleavage products of this reaction, and provides a method for cleaving a neisserial polypeptide, comprising the step of mixing the polypeptide with a lactoferrin enzyme. The invention also provides polypeptides obtainable by this process (i.e. the cleavage products of the lactoferrin digestion). Proteins of particular interest are meningococcal proteins 287 and App.Type: GrantFiled: April 28, 2005Date of Patent: December 18, 2012Assignee: Novartis AGInventors: Davide Serruto, Maria Aricò
